Distinct Humoral Response Development to Measles Virus across Vaccine Platforms 2251461

Abstract Introduction As measles incidences increase globally, it is imperative to elucidate the features of a protective humoral response. Methods In this study, a phage-display immunoprecipitation sequencing technology, VirScan, was employed to evaluate viral epitope coverage by antibodies raised to infection of rhesus macaques with wild-type (WT) measles virus (MeV), or after vaccination with a live-attenuated MeV vaccine (LAMV), the triple measles mumps rubella vaccine (MMR) or a novel recombinant MeV hemagglutinin protein-based vaccine (rMeVH). Vaccinated animals were also challenged with WT MeV to measure antibody epitope reactivity during a recall. Results The results demonstrate that WT MeV infection elicited antibodies with a broader epitope reactivity profile than LAMV-containing vaccines. The rMeVH vaccine not only resulted in a narrow H-protein specific antibody profile, but induced specificities that were distinct from those induced to WT MeV or LAMV. All vaccinated animals expanded the breadth of their MeV-specific antibody binding repertoires following WT MeV challenge. The MeV-specific VarScore, a measure of overall antigen-binding, was positively correlated with total IgG titers assessed by ELISA, avidity, and neutralizing titer. Conclusion These results demonstrate the large effects of vaccination platforms on the breadth and fine-specificity of anti-measles induced humoral responses. Funding Source NIH Topic Categories Vaccines and Immunotherapy (VAC)